+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2015-09-21Number of Pages: 77

Heparin Market (By Product: Unfractionated Heparin, Low Molecular Weight Heparin, Ultra-Low Molecular Weight Heparin; By Geography: North America, Europe, Asia Pacific and Rest of the World) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023

Heparin is an anticoagulant that is primarily used to prevent and treat venous thrombosis, pulmonary embolism, and other conditions of blood clotting. This report provides in-depth analysis of the global heparin market. Stakeholders for this report include manufacturers of heparin products, crude heparin suppliers, heparin processing companies, and new players planning to enter the market. The global heparin market has been studied from two perspectives: by products and by geography. The heparin market, by products, comprises unfractionated heparin, low molecular weight heparin, and ultra-low molecular weight heparin. A detailed market analysis and forecast for each of these segments have been provided in this study in terms of market revenue (USD million) for the period from 2013 to 2023. The report also provides compounded annual growth rate (CAGR %) for each of these segments for the forecast period from 2015 to 2023, considering 2013 and 2014 as historical and base years, respectively. Furthermore, the heparin market, by geography, includes North America, Europe, Asia Pacific, and Rest of the World. Each of these regions has been sub-segmented and analyzed for major contributing countries.

 

The market overview section of the report demonstrates major market dynamics such as drivers, restraints and opportunities that influence the current and future status of this industry. The market overview section includes Porter’s Five Forces Analysis and market attractiveness analysis by geography coupled with qualitative analysis on regulatory scenarios, impact analysis of key industry events, and value chain analysis to provide a thorough analysis of the overall competitive scenario in the global heparin market. The market overview section of the report also includes the qualitative and quantitative analysis of the competitive landscape.

 

Market share analysis is also provided in the market overview section of the report for 2014 in terms of value (%). The report also provides important recommendations for market players and new entrants. These recommendations would enable existing market players to expand their market share and help new companies establish their presence in the heparin market in Europe. The report concludes with the company profiles section, which includes key information about major players in the market such as financial overview, business strategies, and recent developments. Key players mentioned in the report include Dr. Reddy's Laboratories Ltd., Fresenius Kabi AG, LEO Pharma A/S, Mylan N.V., Pfizer, Inc., Sanofi S.A., Syntex S.A., and Teva Pharmaceutical Industries Ltd.

The global heparin market is segmented into the following categories:

 

Global Heparin Market, by Product

  • Unfractionated Heparin
  • Low Molecular Weight Heparin (LMWHs)
  • Ultra-low Molecular Weight Heparin (ULMWHs)

 

Global Heparin Market, by Geography

  • North America
    • United States
    • Canada
  • Europe
    • Germany
    • United Kingdom
    • France
    • Rest of the Europe
  • Asia Pacific
    • India
    • China
    • Japan
    • Rest of Asia Pacific
  • Rest of the World
    • Latin America
    • Africa
    • Other Countries


Chapter 1 Introduction
1.1 Report Description
1.2 Research Methodology
      1.2.1 Secondary Research
      1.2.2 Primary Research
1.3 Market Segmentation
1.4 Assumptions and Stipulations

Chapter 2 Executive Summary

Chapter 3 Market Overview
3.1 Introduction
3.2 Market Drivers
      3.2.1 High incidence and mortality associated with coagulation disorders to propel the demand for heparin
      3.2.2 Commercialization of safe and cost-effective heparin products
3.3 Market Restraints
      3.3.1 Presence of alternative anticoagulants impeding the sale of biological heparin products
      3.3.2 Decreased import of heparin from China leading to enhanced quality control measures, thereby elevating the cost of heparin production
3.4 Market Opportunities
      3.4.1 Advent of biosimilars to create new opportunities for manufacturers
      3.4.2 Research activities on marine-based heparin products can lead to introduction of novel products
3.5 Porter’s Five Forces Analysis for Global Heparin Market
      3.5.1 Bargaining Power of Suppliers
      3.5.2 Bargaining Power of Buyers
      3.5.3 Threats of Substitutes
      3.5.4 Threat of New Entrants
      3.5.5 Competitive Rivalry
3.6 Value Chain Analysis: Global Heparin Market
3.7 Event Impact Analysis
3.8 Regulatory Framework
3.9 Market Attractiveness Analysis: Global Heparin Market, by Geography
3.10 Market Share Analysis: Global Heparin Market, by Key Players, 2014

Chapter 4 Global Heparin Market, by Product
4.1 Introduction
      4.1.1 Global Heparin Market Revenue, by Products, 2013 – 2023 (USD Million)
4.2 Unfractionated Heparin
      4.2.1 Global Unfractionated Heparin Market Revenue, 2013 – 2023 (USD Million)
4.3 Low Molecular Weight Heparin
      4.3.1 Global Low Molecular Weight Heparin Market Revenue, 2013 – 2023 (USD Million)
4.4 Ultra-low Molecular Weight Heparin
      4.4.1 Global Ultra-low Molecular Weight Heparin Market Revenue, 2013 – 2023 (USD Million)

Chapter 5 Global Heparin Market, by Geography
5.1 Overview
      5.1.1 Global Heparin Market Revenue, by Country, 2013 – 2023 (USD Million)
5.2 North America
      5.2.1 United States Heparin Market Revenue, by Product Type 2013 – 2023 (USD Million)
5.3 Europe
      5.3.1 Europe Heparin Market Revenue, by Product Type 2013 – 2023 (USD Million)
5.4 Asia Pacific
      5.4.1 Asia Pacific Heparin Market Revenue, by Product Type 2013 – 2023 (USD Million)
5.5 Rest of the World
      5.5.1 Rest of the World Heparin Market Revenue, by Product Type 2013 – 2023 (USD Million)

Chapter 6 Recommendations
6.1 Focus on enhancing product quality and efficacy of generic/biosimilar products
6.2 Focus on alternative sources to overcome demand-supply gap

Chapter 7 Company Profiles
7.1 Dr. Reddy’s Laboratories Ltd.
      7.1.1 Company Overview
      7.1.2 Financial Overview
      7.1.3 Product Portfolio
      7.1.4 Business Strategies
      7.1.5 Recent Developments
7.2 Fresenius Kabi AG
      7.2.1 Company Overview
      7.2.2 Financial Overview
      7.2.3 Product Portfolio
      7.2.4 Business Strategies
      7.2.5 Recent Developments
7.3 LEO Pharma A/S
      7.3.1 Company Overview
      7.3.2 Financial Overview
      7.3.3 Product Portfolio
      7.3.4 Business Strategies
      7.3.5 Recent Developments
7.4 Mylan N.V.
      7.4.1 Company Overview
      7.4.2 Financial Overview
      7.4.3 Product Portfolio
      7.4.4 Business Strategies
      7.4.5 Recent Developments
7.5 Pfizer, Inc.
      7.5.1 Company Overview
      7.5.2 Financial Overview
      7.5.3 Product Portfolio
      7.5.4 Business Strategies
      7.5.5 Recent Developments
7.6 Sanofi S.A.
      7.6.1 Company Overview
      7.6.2 Financial Overview
      7.6.3 Product Portfolio
      7.6.4 Business Strategies
      7.6.5 Recent Developments
7.7 Syntex S.A.
      7.7.1 Company Overview
      7.7.2 Financial Overview
      7.7.3 Product Portfolio
      7.7.4 Business Strategies
      7.7.5 Recent Developments
7.8 Teva Pharmaceutical Industries Ltd.
      7.8.1 Company Overview
      7.8.2 Financial Overview
      7.8.3 Product Portfolio
      7.8.4 Recent Developments

List of Figures

FIG. 1 Global Heparin Market Segmentation
FIG. 2 Global Heparin Market, by Products, 2014 (USD Million)
FIG. 3 Porter’s Five Forces Analysis: Global Heparin Market
FIG. 4 Value Chain Analysis: Global Heparin Market
FIG. 5 Market Attractiveness Analysis: Global Heparin Market, by Geography, 2014
FIG. 6 Market Share Analysis: Global Heparin Market, by Key Players, 2014 (Value %)
FIG. 7 Global Unfractionated Heparin Market Revenue, 2013 – 2023 (USD Million)
FIG. 8 Global Low Molecular Weight Heparin Market Revenue, 2013 – 2023 (USD Million)
FIG. 9 Global Ultra-low Molecular Weight Heparin Market Revenue, 2013 – 2023 (USD Million)
FIG. 10 Dr. Reddy's Laboratories Ltd.: Annual Revenue, 2012 – 2014 (USD Million)
FIG. 11 Fresenius Group: Annual Revenue, 2012 – 2014 (USD Million)
FIG. 12 LEO Pharma A/S: Annual Revenue, 2012 – 2014 (USD Million)
FIG. 13 Mylan N.V.: Annual Revenue, 2012 – 2014 (USD Million)
FIG. 14 Pfizer, Inc.: Annual Revenue, 2012 – 2014 (USD Million)
FIG. 15 Sanofi S.A.: Annual Revenue, 2012 – 2014 (USD Million)
FIG. 16 Teva Pharmaceutical Industries Ltd.: Annual Revenue, 2012 – 2014 (USD Million)

List of Tables

TABLE 1 Market Snapshot: Europe Heparin Market
TABLE 2 Global Heparin Market Revenue, by Products, 2013 – 2023 (USD Million)
TABLE 3 Global Heparin Market Revenue, by Country, 2013 – 2023 (USD Million)
TABLE 4 United States Heparin Market Revenue, by Product Type, 2013 – 2023 (USD Million)
TABLE 5 Europe Heparin Market Revenue, by Product Type, 2013 – 2023 (USD Million)
TABLE 6 Asia Pacific Heparin Market Revenue, by Product Type, 2013 – 2023 (USD Million)
TABLE 7 Rest of the World Heparin Market Revenue, by Product Type, 2013 – 2023 (USD Million)

Heparin is an anticoagulant used for decreasing the clotting ability of the blood. It is either used as a calcium or sodium salt in the prophylaxis and treatment of clotting disorders, blood transfusion, and blood sampling. Treatment of venous thromboembolism (VTE) includes deep vein thrombosis (DVT) and pulmonary embolism (PE) along with increasing number of surgical procedures are the major drivers for global heparin market.  

The global heparin market has been studied from two perspectives: by products and by geography. The market by products encompasses unfractionated heparin, low molecular weight heparin (LMWHs) and ultra-low molecular weight heparin (ULMWHs). Unfractionated heparin is a naturally occurring polysaccharide that works as an anticoagulant by inhibiting the activity of several blood coagulation factors. Although unfractionated heparin is one of the most primitive forms of heparin, the narrow therapeutic window and risk associated with bleeding act as the major restraints to its market across the globe. Unfractionated heparin is primarily used in dialysis and heart lung machines to prevent blood clots. However, recent trends especially in developed countries are now gradually shifting towards heparin free dialysis; another key restraint to the unfractionated heparin market. Several studies have also confirmed that unfractionated heparin has more specificity than LMWH, and its effect can be reversed by using protamine sulfate. 

Low molecular weight heparins (LMWHs) are derived from unfractionated heparin with an average molecular weight of less than 8,000 Da. Low molecular weight heparin is the most widely used heparin product and accounted for the largest market share in 2014. Furthermore, the National Institute for Health and Care Excellence (NICE) and the Royal College of Obstetrics and Gynaecology (RCOG) recommends LMWH as the most appropriate heparin form to be used during pregnancy due to its inability to cross the placenta. Patent expiration for majority of LMWHs have already created a huge latent opportunity for generic and biosimilar manufacturers in the forthcoming years. Ultra-low molecular weight heparin is the most novel therapeutic among the heparin product family. Bemiparin and Fondaparinux sodium are the two major ultra-low molecular weight heparins sold globally. Fondaparinux with different strength and formulations are approved in the U.S. and Europe for indications such as acute coronary syndrome (ACS), acute symptomatic spontaneous superficial-vein thrombosis (SVT) of the lower limbs without concomitant deep vein thrombosis (DVT), and pulmonary embolism (PE). Despite its therapeutic ability, high cost associated with its processing and manufacturing is affecting the sale and demand of ULMWHs across the globe. 

The global heparin market by geography has been studied for North America, Europe, Asia Pacific and Rest of the World. Each of these regional markets is further analyzed and estimated by prominent countries. Approximately 50% of DVT/PE patients develop long-term complications and one-third would have a recurrence within 10 years in the U.S. A 2014 presentation by the U.S. FDA depicted that around 75% of the crude porcine heparin used for API manufacturing in the U.S. is outsourced from other countries. Recently (2014) the Center for Drug Evaluation and Research (CDER), U.S. proposed to re-introduce bovine sourced heparin which was banned in 90’s as a measure to curb any outbreak of bovine spongiform encephalopathy (BSE). 

Followed by North America, Europe is a major contributor to the global heparin market owing to burgeoning geriatric population base and rising incidences of coagulation disorders. According to the National Health Service (NHS), DVT affects one in every 1,000 persons each year in the U.K. Moreover, the NHS also reports that DVT becomes more common with age due to the risk of medical conditions such as heart failure, cancer, obesity, and inactivity, which then leads to the occurrence of DVT. Asia Pacific (APAC) and Rest of the World (RoW) are largely untapped and expected to be the fastest growing markets during the forecast period. Data from the National Institute of Health Consensus depicted that the overall incidence of DVT after elective hip surgery in India is around 45% to 70%, whereas the probability of PE is approximately 20%. Growing economy, healthcare infrastructure and increasing number of surgical procedures in APAC and ROW are likely to boost heparin market in these regions. 

Key players covered in the report include Dr. Reddy's Laboratories Ltd., Fresenius Kabi AG, LEO Pharma A/S, Mylan N.V., Pfizer, Inc., Sanofi S.A., Syntex S.A., and Teva Pharmaceutical Industries Ltd.

 

heparin-market

 


A complete brochure for this research is available for download.

Interact with our pool of experienced analysts for any report related queries